logo
Plus   Neg
Share
Email

Roche Reports Positive Data From Phase III IMpower110 Study With Tecentriq

Roche (RHHBY.PK) said a Phase III IMpower110 study evaluating Tecentriq as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine in advanced non-squamous and squamous non-small cell lung cancer met its primary endpoint in an interim analysis showing that Tecentriq monotherapy demonstrated a statistically significant overall survival. Roche said it will now submit the data to global health authorities, including the FDA and EMA.

Also, the company announced that a full pivotal phase III study to treat neuromyelitis optica spectrum disorder showed that satralizumab monotherapy achieved a 55% reduction in the risk of relapses compared to placebo in the overall population.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google announced a batch of renewable energy deals totaling 1.6 GW through 18 acquisitions spread across three continents. The deals are intended to "spur the construction of more than $2 billion in new energy infrastructure," the company said. Google said the deals will increase its worldwide portfolio... Beyond Meat's main competitor Impossible Foods will launch its grocery store in California on Friday. Beyond Meat Inc. (BYND), the meatless burger and sausage maker, announced the appointment of Sanjay Shah as Chief Operating Officer. Shah will assume the responsibility for Beyond Meat's global operations and production, effective September 18.
Follow RTT
>